Rifaximin

From Wikipedia, the free encyclopedia - View original article

Rifaximin
Systematic (IUPAC) name
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25-pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca-[1,11,13]trienimino)benzofuro
[4,5-e]pyrido[1,2-a]-benzimida-zole-1,15(2H)-dione,25-acetate
Clinical data
Trade namesXifaxan, Xifaxanta, Normix
AHFS/Drugs.commonograph
MedlinePlusa604027
Pregnancy cat.C (US)
Legal status Prescription only
RoutesOral
Pharmacokinetic data
Bioavailability< 0.4%
MetabolismHepatic
Half-life6 hours
ExcretionFecal (97%)
Identifiers
CAS number80621-81-4 YesY
ATC codeA07AA11 D06AX11 QG51AA06 QJ51XX01
PubChemCID 6436173
DrugBankDB01220
ChemSpider10482302 YesY
UNIIL36O5T016N YesY
KEGGD02554 YesY
ChEMBLCHEMBL1617 YesY
Chemical data
FormulaC43H51N3O11 
Mol. mass785.879 g/mol
 YesY (what is this?)  (verify)
 
Jump to: navigation, search
Rifaximin
Systematic (IUPAC) name
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25-pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca-[1,11,13]trienimino)benzofuro
[4,5-e]pyrido[1,2-a]-benzimida-zole-1,15(2H)-dione,25-acetate
Clinical data
Trade namesXifaxan, Xifaxanta, Normix
AHFS/Drugs.commonograph
MedlinePlusa604027
Pregnancy cat.C (US)
Legal status Prescription only
RoutesOral
Pharmacokinetic data
Bioavailability< 0.4%
MetabolismHepatic
Half-life6 hours
ExcretionFecal (97%)
Identifiers
CAS number80621-81-4 YesY
ATC codeA07AA11 D06AX11 QG51AA06 QJ51XX01
PubChemCID 6436173
DrugBankDB01220
ChemSpider10482302 YesY
UNIIL36O5T016N YesY
KEGGD02554 YesY
ChEMBLCHEMBL1617 YesY
Chemical data
FormulaC43H51N3O11 
Mol. mass785.879 g/mol
 YesY (what is this?)  (verify)

Rifaximin is a semisynthetic antibiotic based on rifamycin. It has poor oral bioavailability, meaning that very little of the drug will be absorbed into the blood stream when it is taken orally. Rifaximin is used in the treatment of traveler's diarrhea and hepatic encephalopathy, for which it received orphan drug status from the U.S. Food and Drug Administration in 1998.

Uses[edit source | edit]

Rifaximin is licensed by the U.S. Food and Drug Administration to treat traveler's diarrhea caused by E. coli.[1] Clinical trials have shown that rifaximin is highly effective at preventing and treating traveler's diarrhea among travelers to Mexico, with few side effects and low risk of developing antibiotic resistance.[2][3][4] It is not effective against Campylobacter jejuni, and there is no evidence of efficacy against Shigella or Salmonella species.

It may be efficacious in relieving chronic functional symptoms of bloating and flatulence that are common in irritable bowel syndrome.[5][6]

There was recently a pilot-study done on the efficacy of rifaximin as a means of treatment for rosacea, according to the study, induced by the co-presence of small intestinal bacterial overgrowth.[7]

In the United States, rifaximin has orphan drug status for the treatment of hepatic encephalopathy.[8] Although high-quality evidence is still lacking, rifaximin appears to be as effective as or more effective than other available treatments for hepatic encephalopathy (such as lactulose), is better tolerated, and may work faster.[9] The drawbacks to rifaximin are increased cost and lack of robust clinical trials for HE without combination lactulose therapy.

Mechanism of action[edit source | edit]

Rifaximin interferes with transcription by binding to the β-subunit of bacterial RNA polymerase. This results in the blockage of the translocation step that normally follows the formation of the first phosphodiester bond, which occurs in the transcription process. [10]

Efficacy[edit source | edit]

A 2011 study in patients with Irritable bowel syndrome without Constipation shows that 11% of patients show benefit over a placebo.[11] The study was supported by Salix Pharmaceuticals, the patent holder. [12] A 2010 study in patients treated for Hepatic Cirrhosis with hospitalization involving Hepatic encephalopathy resulted in 22% of the Rifaxmin treated group experiencing a breakthrough episode of Hepatic encephalopathy as compared to 46% of the placebo group. The majority patients were also receiving Lactulose therapy for prevention of hepatic encephalopathy in addition to Rifaximin.[13]

Availability[edit source | edit]

In the United States, Salix Pharmaceuticals holds a US Patent for rifaximin and markets the drug under the name Xifaxan, available in tablets of 200 mg and 550 mg.[14][15] While FDA approved for traveler’s diarrhea and (marketing approved for)[16] hepatic encephalopathy, Xifaxan has not yet received FDA approval for IBS. Medical insurance may not cover drug costs when prescribed for “off-label” uses, such as Xifaxan prescribed for IBS. No generic formulation is available in the US and none will appear while the FDA approval process is ongoing. If Xifaxan receives full FDA approval for hepatic encephalopathy it is likely that Salix will maintain marketing exclusivity and be protected from generic formulations until March 24, 2017.[17] Price quotes received on February 21, 2013 for Xifaxan 550 mg in the Denver Metro area were between $23.57 and $26.72 per tablet.

Rifaximin is approved in 33 countries for GI disorders,[18][19] but, as of February 21, 2013, is not approved for use in Canada and has not been issued a Drug Identification Number (DIN) by Health Canada.[20] While lower cost, generic formulations of rifaximin may be offered via Canadian web domains, these products have not been evaluated or authorized for sale in Canada and may not be in compliance with Canadian law. The Canadian government, via Health Canada, has warned of the dangers of purchasing drugs over the internet.[21] The US government, through the FDA,[22][23][24][25][26] and the National Association of Boards of Pharmacy[27] are among other organizations that have issued similar warnings about “Canadian” and other drugs available online and offer resources for consumers to help ensure the safety of internet drugs. [28][29][30] In India it is available under the brand name of CIBOZ.[citation needed]

References[edit source | edit]

  1. ^ Xifaxan label information PDF Retrieved November 15, 2008.
  2. ^ DuPont, H (2007). "Therapy for and Prevention of Traveler's Diarrhea". Clinical Infectious Diseases 45 (45 (Suppl 1)): S78–S84. doi:10.1086/518155. PMID 17582576. 
  3. ^ Ruiz J, Mensa L, Pons MJ, Vila J, Gascon J (May 2008). "Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability". Journal of antimicrobial chemotherapy 61 (5): 1016–9. doi:10.1093/jac/dkn078. PMID 18325895. 
  4. ^ Martinez-Sandoval F, Ericsson CD, Jiang ZD, Okhuysen PC, Romero JH, Hernandez N, Forbes WP, Shaw A, Bortey E, DuPont HL. (2010 Mar-Apr). "Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico.". J Travel Med. 17 (2): 111-7. doi:10.1111/j.1708-8305.2009.00385.x. PMID 20412178. 
  5. ^ Sharara A, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, ElHajj I. (2006). "A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence". Am J Gastroenterol 101 (2): 326–33. doi:10.1111/j.1572-0241.2006.00458.x. PMID 16454838. 
  6. ^ Antibiotic May Help Ease Irritable Bowel, Businessweek, January 05, 2011
  7. ^ Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Parodi A, Paolino S, Greco A, Drago F, Mansi C, Rebora A, Parodi A, Savarino V.
  8. ^ Wolf, David C. (2007-01-09). "Hepatic Encephalopathy". eMedicine. WebMD. Retrieved 2007-02-15. 
  9. ^ Lawrence KR, Klee JA (2008). "Rifaximin for the treatment of hepatic encephalopathy". Pharmacotherapy 28 (8): 1019–32. doi:10.1592/phco.28.8.1019. PMID 18657018.  Free full text with registration at Medscape.
  10. ^ http://www.drugbank.ca/drugs/DB01220
  11. ^ http://www.nejm.org/doi/full/10.1056/NEJMoa1004409#t=article
  12. ^ http://www.nejm.org/doi/full/10.1056/NEJMoa1004409#t=article
  13. ^ Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081. PMID: 20335583
  14. ^ http://www.salix.com/products/xifaxan550.aspx
  15. ^ http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=022554&TABLE1=OB_Rx
  16. ^ http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=022554&TABLE1=OB_Rx
  17. ^ http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=022554&TABLE1=OB_Rx
  18. ^ http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM203248.pdf
  19. ^ http://www.salix.com/news-media/news/previous-years-news/fda-approves-xifaxan%C2%AE-550-mg-tablets-for-reduction-in-risk-of-overt-hepatic-encephalopathy-he-recurrence.aspx
  20. ^ http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/fs-fi/dinfs_fd-eng.php
  21. ^ http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/internet-eng.php
  22. ^ http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/BeSafeRxKnowYourOnlinePharmacy/default.htm
  23. ^ http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm321068.htm
  24. ^ http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/default.htm
  25. ^ http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm289143.htm#ODSIR
  26. ^ http://www.fda.gov/forconsumers/consumerupdates/ucm048164.htm
  27. ^ http://www.nabp.net/programs/consumer-protection/buying-medicine-online
  28. ^ http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/BeSafeRxKnowYourOnlinePharmacy/default.htm
  29. ^ http://www.nabp.net/programs/accreditation/vipps/
  30. ^ http://www.nabp.net/programs/accreditation/vet-vipps/

External links[edit source | edit]